A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Conditions
HNSCC · ESCC · Esophageal Adenocarcinoma · Gastric Adenocarcinoma · GEJ Adenocarcinoma · Ovarian Cancer · NSCLC · Cervical Cancer · Endometrial Cancer · Triple Negative Breast Cancer (TNBC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Normunity Investigational Site, Denver, Colorado, United States
Normunity Investigational Site, New Haven, Connecticut, United States
Normunity Investigational Site, Minneapolis, Minnesota, United States
Normunity Investigational Site, Maumee, Ohio, United States
Normunity Investigational Site, Philadelphia, Pennsylvania, United States
Normunity Investigational Site, Nashville, Tennessee, United States
Normunity Investigational Site, Dallas, Texas, United States
Normunity Investigational Site, San Antonio, Texas, United States
Normunity Investigational Site, Fairfax, Virginia, United States
Study leads
Viviana Bozon, MD
Study Director
Normunity AccelCo, Inc.